ReviewPain management2025
Opioid deprescribing: rethinking policies to facilitate better patient outcomes.
Review in Pain management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient- and Clinician-Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non-Cancer Pain: A Systematic Review.Clinical pharmacology and therapeutics · 2026Pooled it
- Safer supply deprescribing during a toxic drug poisoning crisis in Vancouver, Canada.Drug and alcohol dependence · 2026Article
- Rural Clinicians Efforts to Maintain Relationship-Centered Care Amidst Conflicting Tensions with Inherited Opioid Prescribing Practices.Journal of general internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deprescribing, the patient-centered process of reducing or stopping a medication when the potential harms outweigh the likely benefits, has emerged as a promising strategy to mitigate opioid-related harm. Typically, opioid deprescribing occurs at the individual level, however, adopting a policy-driven approach could expand its reach and impact. To date, prescription opioid control policies that have been implemented with the intention of reducing opioid use and harm have often resulted in unintended consequences. In this article we discuss whether and how the concept of opioid deprescribing can be operationalized at a policy level. We review the goals, challenges and consequences of opioid control policies, explore how they intersect with system-level factors, and propose pathways for developing and implementing future opioid deprescribing policies. We argue that the development and implementation of patient-centered opioid deprescribing policies are both essential and feasible, if key challenges such as structural stigma and the complex interplay between pain and opioid use disorder are recognized and addressed. Robust evaluation frameworks will also be critical for monitoring outcomes and refining interventions. By prioritizing patient and provider needs, and carefully considering pertinent system-level factors, policymakers may be able to foster more effective and compassionate opioid management and reduce opioid-related harm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.